Phibro Animal Health
PAHC
37.72
+1.11
+3.03%
Phibro Animal Health
US · PAHC
#2966 by market cap
Listed 1970
37.72
+1.11
+3.03%
Live - 5344 symbols - heartbeat 532s ago
· 2026-10-08 07:00
Pre-market
37.72
0.00%
After-hours
37.72
0.00%
- Market cap
- 1.53B
- P/E (TTM)i
- 15.52
- P/Bi
- 3.97
- EPSi
- 2.43
- Div yieldi
- 1.27%
- 52W posi
- 31%
Reader sentiment
Are you bullish or bearish on PAHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.09, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +17.12% YoY
Margins
- Gross margin
- 33.76%
- Operating margin
- 12.81%
- Net margin
- 6.57%
Key ratios & quality
- Enterprise valuei
- 2.19B
- PEG ratioi
- 0.34
- Altman Z-Scorei
- 3.09
PEG uses trailing P/E against the 3-year net income growth rate (45.15%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 828.00M | 800.35M | 833.35M | 942.26M | 977.89M | 1.02B | 1.30B | 1.52B |
| Gross profit | 264.62M | 256.88M | 271.38M | 285.40M | 298.24M | 313.09M | 399.94M | 512.52M |
| Selling & admin expenses | 181.40M | 187.69M | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M | 318.12M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 83.23M | 69.19M | 74.87M | 78.99M | 71.85M | 53.32M | 110.47M | 194.40M |
| Pretax profit | 71.51M | 55.51M | 66.47M | 72.33M | 54.07M | 10.92M | 67.99M | 137.35M |
| Tax | 16.79M | 21.96M | 12.08M | 23.15M | 21.47M | 8.50M | 19.73M | 37.63M |
| Net profit | 54.71M | 33.55M | 54.39M | 49.18M | 32.61M | 2.42M | 48.26M | 99.72M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 |
| Diluted EPS | 1.35 | 0.83 | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 | 2.43 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 347.83M | 378.70M | 363.89M | 373.91M | 383.54M | 396.75M |
| Gross profit | 104.57M | 110.01M | 119.78M | 132.66M | 125.68M | 134.40M |
| Selling & admin expenses | 71.05M | 76.29M | 68.52M | 82.33M | 81.02M | 86.24M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 33.52M | 33.72M | 51.26M | 50.33M | 44.65M | 48.16M |
| Pretax profit | 29.69M | 23.85M | 36.27M | 36.43M | 32.31M | 32.34M |
| Tax | 8.81M | 6.62M | 9.74M | 8.97M | 8.29M | 10.63M |
| Net profit | 20.88M | 17.22M | 26.53M | 27.46M | 24.02M | 21.71M |
| Basic EPS | 1 | 0 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.51 | 0.42 | 0.65 | 0.67 | 0.59 | 0.53 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 466.16M | 451.84M | 498.91M | 566.23M | 585.72M | 601.00M | 810.61M | 935.51M |
| Cash & ST investments | 81.57M | 91.34M | 93.21M | 91.25M | 81.28M | 114.61M | 77.04M | 81.99M |
| Inventory | 198.32M | 196.66M | 216.31M | 259.16M | 277.57M | 265.91M | 444.43M | 534.88M |
| Total assets | 726.67M | 784.10M | 841.33M | 931.70M | 971.40M | 982.18M | 1.36B | 1.50B |
| Total current liabilities | 154.23M | 157.24M | 164.12M | 190.83M | 176.00M | 204.15M | 293.47M | 316.47M |
| Short-term debt | 12.54M | 25.19M | 15.99M | 21.05M | 28.35M | 37.26M | 25.38M | 35.60M |
| Long-term debt | 313.64M | 368.26M | 382.71M | 417.93M | 452.54M | 458.29M | 702.44M | 707.77M |
| Total liabilities | 510,656,000.00 | 595,896,000.00 | 602,796,000.00 | 669,257,000.00 | 688,888,000.00 | 725,543,000.00 | 1,075,218,000.00 | 1,115,764,000.00 |
| Total equity | 216.02M | 188.20M | 238.53M | 262.44M | 282.51M | 256.64M | 285.68M | 385.48M |
| Retained earnings | 168.93M | 183.06M | 218.02M | 247.75M | 260.91M | 243.89M | 272.70M | 352.96M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 776.02M | 810.61M | 835.80M | 862.19M | 894.07M | 935.51M |
| Cash & ST investments | 70.35M | 77.04M | 85.27M | 74.51M | 77.45M | 81.99M |
| Inventory | 448.39M | 444.43M | 471.78M | 517.35M | 539.70M | 534.88M |
| Total assets | 1.32B | 1.36B | 1.39B | 1.41B | 1.45B | 1.50B |
| Total current liabilities | 266.48M | 293.47M | 270.14M | 282.37M | 281.87M | 316.47M |
| Short-term debt | 25.24M | 25.38M | 27.47M | 29.60M | 32.25M | 35.60M |
| Long-term debt | 711.16M | 702.44M | 724.52M | 710.60M | 712.69M | 707.77M |
| Total liabilities | 1,051,268,000.00 | 1,075,218,000.00 | 1,073,843,000.00 | 1,073,192,000.00 | 1,083,291,000.00 | 1,115,764,000.00 |
| Total equity | 265.99M | 285.68M | 311.68M | 332.36M | 361.83M | 385.48M |
| Retained earnings | 260.34M | 272.70M | 294.36M | 316.96M | 336.12M | 352.96M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 47.17M | 59.35M | 48.31M | 31.65M | 13.31M | 87.59M | 80.12M | 68.95M |
| Depreciation & amortization | 27.56M | 32.34M | 31.88M | 32.71M | 34.01M | 36.18M | 45.61M | 51.51M |
| Free cash flow | 17.28M | 25.30M | 18.99M | -5.40M | -38.48M | 46.36M | 41.83M | 9.87M |
| Dividends paid | -18.59M | -19.42M | -19.43M | -19.44M | -19.44M | -19.44M | -19.45M | -19.46M |
| Stock buybacks / issuance | 1.13M | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 57.57M | 36.34M | 50.21M | 74.25M | 41.28M | 70.61M | 68.04M | 61.42M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 43.15M | 21.27M | 9.30M | 19.35M | 16.21M | 24.09M |
| Depreciation & amortization | 12.62M | 12.41M | 12.83M | 12.89M | 12.45M | 13.35M |
| Free cash flow | 35.41M | 8.13M | -4.50M | 8.26M | 890.00K | 5.23M |
| Dividends paid | -4.87M | -4.86M | -4.86M | -4.86M | -4.87M | -4.87M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 60.35M | 68.04M | 72.77M | 55.49M | 54.93M | 61.42M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 27.29 | 16.60 | 25.49 | 19.63 | 11.97 | 0.90 | 17.80 | 29.72 |
| ROA %i | 7.83 | 4.44 | 6.69 | 5.55 | 3.43 | 0.25 | 4.12 | 6.97 |
| ROIC %i | 12.26 | 7.15 | 10.14 | 8.13 | 5.43 | 1.96 | 7.65 | 11.73 |
| 5-year avg ROE %i | 105.28 | 54.75 | 32.29 | 25.52 | 20.20 | 14.92 | 15.16 | 16.00 |
| EBIT margin %i | 10.29 | 8.65 | 9.50 | 8.96 | 7.36 | 3.23 | 7.81 | 11.95 |
| FCF / sales %i | 2.09 | 3.16 | 2.28 | -- | -- | 4.56 | 3.23 | 0.65 |
| Current ratioi | 3.02 | 2.87 | 3.04 | 2.97 | 3.33 | 2.94 | 2.76 | 2.96 |
| Quick ratioi | 1.56 | 1.39 | 1.46 | 1.35 | 1.39 | 1.39 | 1.04 | 1.01 |
| Debt / assetsi | 44.89 | 52.38 | 50.72 | 50.50 | 52.50 | 53.50 | 55.96 | 52.54 |
| LT debt / equityi | 145.19 | 204.85 | 172.19 | 171.25 | 170.48 | 190.23 | 257.69 | 195.39 |
| Interest coveragei | 6.23 | 5.04 | 6.23 | 6.98 | 4.01 | 1.50 | 3.04 | 4.11 |
| Revenue CAGR (3Y) %i | 3.28 | 1.55 | 0.54 | 4.40 | 6.91 | 6.89 | 11.22 | 15.79 |
| Net income CAGR (3Y) %i | -12.87 | -19.62 | -5.71 | -3.49 | -0.95 | -64.58 | -0.62 | 45.15 |
| FCF CAGR (3Y) %i | 171.22 | -31.14 | -28.28 | -- | -- | 34.66 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 11.86 | 17.80 | 23.79 | 31.80 | 30.34 | 29.72 |
| ROA %i | 2.77 | 4.12 | 5.77 | 6.84 | 6.90 | 6.97 |
| ROIC %i | 5.34 | 7.65 | 9.94 | 11.17 | 11.46 | 11.73 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 6.81 | 7.81 | 9.39 | 11.33 | 11.42 | 11.95 |
| FCF / sales %i | 4.12 | 3.23 | 2.45 | 3.23 | 0.85 | 0.65 |
| Current ratioi | 2.91 | 2.76 | 3.09 | 3.05 | 3.17 | 2.96 |
| Quick ratioi | 1.01 | 1.04 | 1.12 | 1.03 | 1.06 | 1.01 |
| Debt / assetsi | 58.46 | 55.96 | 56.66 | 55.01 | 54.49 | 52.54 |
| LT debt / equityi | 280.00 | 257.69 | 243.08 | 223.72 | 208.72 | 195.39 |
| Interest coveragei | 2.66 | 3.04 | 3.57 | 4.18 | 4.04 | 4.11 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Animal health is the largest reported line at 76.56% of revenue, across 3 reported segments.
- The next-largest line, Mineral Nutrition, is a distant second at 18.60% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Animal health76.56%
Mineral Nutrition18.60%
Performance products4.84%
Region
United States57.78%
Latin America and Canada22.44%
Europe, Middle East and Africa12.38%
Asia Pacific7.40%
Quote time 2026-10-08 07:00:11 · For reference only, not investment advice and not tailored to your situation.